Name: Remdesivir triphosphate – GS-443902 – CAS 1355149-45-9
SKU: 16061
Availability: InStock

Remdesivir triphosphate (GS-443902) structure

Remdesivir triphosphate – GS-443902 – CAS 1355149-45-9

€650 – €5090

Remdesivir triphosphate is synthesised by Santiago Lab (Prague, Czech Republic).

We are providing Remdesivir triphosphate in the form of Et₃NH⁺ salt or Na⁺ salt. All products are lyophilized and can easily sustain the shipment oversee (shipping with DHL on dry ice to ensure that product arrives in a perfect state).

Purity (LC-MS)

99%+ | Certificate of Analysis

Package contents

Remdesivir triphosphate salt

This compound is for research use only. We do not sell to patients.

Size	Availability	Price	Quantity
1 mg	In stock	€650	Remdesivir triphosphate – GS-443902 – CAS 1355149-45-9 quantity
5 mg	In stock	€780	Remdesivir triphosphate – GS-443902 – CAS 1355149-45-9 quantity
10 mg	In stock	€1115	Remdesivir triphosphate – GS-443902 – CAS 1355149-45-9 quantity
25 mg	In stock	€1960	Remdesivir triphosphate – GS-443902 – CAS 1355149-45-9 quantity
50 mg	In stock	€3220	Remdesivir triphosphate – GS-443902 – CAS 1355149-45-9 quantity
100 mg	In stock	€5090	Remdesivir triphosphate – GS-443902 – CAS 1355149-45-9 quantity
100mM/10μL	In stock	€650	Remdesivir triphosphate – GS-443902 – CAS 1355149-45-9 quantity
10mM/100μL	In stock	€650	Remdesivir triphosphate – GS-443902 – CAS 1355149-45-9 quantity

Description
Additional information

Remdesivir triphosphate (GS-443902)

Characterisation

CAS: 1355149-45-9

IUPAC Name: 2-C-(4-Aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-2,5-anhydro-D-altrononitrile 6-triphosphate

Other names: GS-441524 triphosphate, Remdesivir metabolite, Remdesivir triphosphate metabolite, GS-443902

Molecular weight: 531.21 g/mol,

Molecular formula: C₁₂H₁₆N₅O₁₃P₃

Storage: -20 °C, protect from light, store under argon

Target: SARS-CoV; DNA/RNA Synthesis; RSV; Drug Metabolite

All our products are lyophilized to ensure long shelf life and the best shipping conditions. We already have tens of satisfied clients across three continents.

We are also offering this product as a water solution.

Description

Remdesivir triphosphate is synthesised by Santiago Lab (Prague, Czech Republic). GS-443902 is the active triphosphate metabolite of Remdesivir with activity against zoonotic feline infectious peritonitis virus (FIPV) and severe acute respiratory syndrome (SARS) virus from the Coronaviridae family. GS-443902 (GS-441524 triphosphate) is a potent viral RNA-dependent RNA-polymerases (RdRp) inhibitor with IC₅₀s of 1.1 µM, 5 µM for RSV RdRp and HCV RdRp, respectively.

Remdesivir, developed by Gilead Sciences, is an adenosine prodrug that metabolizes into its active form GS-441524, which interferes with the action of viral RNA-dependent RNA polymerase and evades proofreading by viral exoribonuclease (ExoN), causing a decrease in viral RNA production.

This product is prepared and shipped as Et3NH+ salt. If you are interested in Na+ salt, visit our product page.

We distribute products worldwide

Buy Remdesivir triphosphate now, get your order in 48 hours

Shipping through DHL in 48 hours. We can also arrange shipping on dry ice.
All compounds are safely and rigorously packed
Delivery time 24 hours in Europe, 24-48 hours to USA, Canada, Asia
We have already distributed triphosphates to many countries worldwide (Japan, South Korea, USA, Canada, EU, Israel etc.)
Shipping worldwide for free.

Payment

We are sending the invoice the same day as the shipment
We can modify the invoice for the academic institution so that you can pay orders from grants
Payment terms 30 days net

References

References
1. Shannon, A.; Le, N. T.-T.; Selisko, B.; Eydoux, C.; Alvarez, K.; Guillemot, J.-C.; Decroly, E.; Peersen, O.; Ferron, F.; Canard, B., Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites. Antiviral Res. 2020, 178, 104793.
2. Ju, J.; Li, X.; Kumar, S.; Jockusch, S.; Chien, M.; Tao, C.; Morozova, I.; Kalachikov, S.; Kirchdoerfer, R. N.; Russo, J. J., Nucleotide analogues as inhibitors of SARS-CoV polymerase. bioRxiv 2020, 1-18.
3. Jordan, P. C.; Liu, C.; Raynaud, P.; Lo, M. K.; Spiropoulou, C. F.; Symons, J. A.; Beigelman, L.; Deval, J., Initiation, extension, and termination of RNA synthesis by a paramyxovirus polymerase. PLoS Pathogens 2018, 14 (2), e1006889/1-e1006889/23.
4. Siegel, D.; Hui, H. C.; Doerffler, E.; Clarke, M. O.; Chun, K.; Zhang, L.; Neville, S.; Carra, E.; Lew, W.; Ross, B.; Wang, Q.; Wolfe, L.; Jordan, R.; Soloveva, V.; Knox, J.; Perry, J.; Perron, M.; Stray, K. M.; Barauskas, O.; Feng, J. Y.; Xu, Y.; Lee, G.; Rheingold, A. L.; Ray, A. S.; Bannister, R.; Strickley, R.; Swaminathan, S.; Lee, W. A.; Bavari, S.; Cihlar, T.; Lo, M. K.; Warren, T. K.; Mackman, R. L., Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. J. Med. Chem. 2017, 60 (5), 1648-1661.
5. Clarke, M. O. N. H.; Jordan, R.; Mackman, R. L.; Ray, A. S.; Siegel, D. Preparation of amino acid-containing nucleosides for treating flaviviridae virus infections. 2017-US28243, 2017184668, 20170419., 2017.
6. Warren, T. K.; Jordan, R.; Lo, M. K.; Ray, A. S.; Mackman, R. L.; Soloveva, V.; Siegel, D.; Perron, M.; Bannister, R.; Hui, H. C.; Larson, N.; Strickley, R.; Wells, J.; Stuthman, K. S.; Van Tongeren, S. A.; Garza, N. L.; Donnelly, G.; Shurtleff, A. C.; Retterer, C. J.; Gharaibeh, D.; Zamani, R.; Kenny, T.; Eaton, B. P.; Grimes, E.; Welch, L. S.; Gomba, L.; Wilhelmsen, C. L.; Nichols, D. K.; Nuss, J. E.; Nagle, E. R.; Kugelman, J. R.; Palacios, G.; Doerffler, E.; Neville, S.; Carra, E.; Clarke, M. O.; Zhang, L.; Lew, W.; Ross, B.; Wang, Q.; Chun, K.; Wolfe, L.; Babusis, D.; Park, Y.; Stray, K. M.; Trancheva, I.; Feng, J. Y.; Barauskas, O.; Xu, Y.; Wong, P.; Braun, M. R.; Flint, M.; McMullan, L. K.; Chen, S.-S.; Fearns, R.; Swaminathan, S.; Mayers, D. L.; Spiropoulou, C. F.; Lee, W. A.; Nichol, S. T.; Cihlar, T.; Bavari, S., Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature (London, United Kingdom) 2016, 531 (7594), 381-385.
7. Chun, B. K.; Clarke, M. O. N. H.; Doerffler, E.; Hui, H. C.; Jordan, R.; Mackman, R. L.; Parrish, J. P.; Ray, A. S.; Siegel, D. Preparation of nucleosides and methods for treating Filoviridae virus infections. 2015-14926062 20160122374, 20151029., 2016.
8. Cho, A.; Saunders, O. L.; Butler, T.; Zhang, L.; Xu, J.; Vela, J. E.; Feng, J. Y.; Ray, A. S.; Kim, C. U., Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. Bioorganic & Medicinal Chemistry Letters 2012, 22 (8), 2705-2707.